STRATIFYHF: Artificial intelligence-based decision support system for risk stratification and early detection of heart failure in primary and secondary care

心力衰竭（HF）是一种流行病，目前在欧洲影响多达1500万人。它是一种复杂的临床综合征，表现为心功能受损，与患者生活质量差和医疗费用高有关。临床上对新型人工智能（AI）工具有很高的需求，这些工具将有助于心衰的风险分层、早期诊断和疾病进展评估。这些工具对于迅速启动以证据为基础的预防和治疗策略至关重要，这些策略将改善患者的生活质量，降低发病率和死亡率以及心衰对医疗保健的负担。STRATIFYHF旨在开发、验证和实施首个基于人工智能的决策支持系统（DSS），用于心衰的风险分层、早期诊断和疾病进展评估，以满足初级和二级保健临床需求。DSS将使用现有和新技术整合患者特定的人口统计学和临床数据，并使用机器学习建立基于人工智能的风险分层和心衰预测工具。此外，将开发一个移动应用程序，使患者能够更好地管理自己的病情，并使卫生保健专业人员能够在选择循证心衰预防和治疗策略时做出明智的决定。我们的多学科联盟，包括三家中小型企业和两家利益相关者组织，将在医疗咨询、监管和卫生技术专家的指导下，将DSS作为医疗2b级设备交付，在项目结束时达到TRL 8。STRATIFYHF将改变目前心衰的诊断方式，从而提高患者的生活质量和寿命，并通过减少欧洲及其他地区与心衰相关的住院人数和不必要的从初级保健到二级保健的转诊，建立高效和可持续的医疗保健系统。

Heart failure (HF) is a pandemic currently affecting up to 15 million people in Europe. It is a complex clinical syndrome presenting with impaired heart function and is associated with poor quality of life for patients and high healthcare costs. There is a high clinical demand for novel artificial intelligence (AI) tools which will facilitate risk stratification, early diagnosis, and disease progression assessment in HF. Such tools are essential to allow prompt initiation of evidence-based prevention and treatment strategies which will improve patient quality of life, reduce morbidity and mortality and the HF burden on healthcare. STRATIFYHF aims to develop, validate and implement the first AI-based, decision support system (DSS) for risk stratification, early diagnosis, and disease progression assessment in HF to accommodate both primary and secondary care clinical needs. The DSS will integrate patient-specific demographic and clinical data using existing and novel technologies and establish AI-based tools for risk stratification and HF prediction using machine learning. Additionally, a mobile app will be developed to empower patients to better manage their condition, and health care professionals to make informed decision in selection of evidence-based HF prevention and treatment strategies. Our multidisciplinary consortium, including three small-to-medium enterprises(SMEs) and two stakeholder organisations, will be guided by medical advice and regulatory and health technology experts to deliver the DSS as a medical class 2b device, reaching TRL 8 by the end of the project. STRATIFYHF will change the way in which HF is diagnosed today and thereby improve the quality and length of patients’ lives and lead to efficient and sustainable healthcare systems by reducing the number of HF-related hospital admissions and unnecessary referrals from primary to secondary care in Europe and beyond.